A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
National Institutes of Health Clinical Center (CC)
Arcus Biosciences, Inc.
M.D. Anderson Cancer Center
Eli Lilly and Company
National University Hospital, Singapore
University of Massachusetts, Worcester
National Cancer Institute (NCI)
National Cancer Institute (NCI)
NYU Langone Health